Pharmaron Beijing Co., Ltd.

300759

CNE100003JW4

Biotechnology & Medical Research

End-of-day quote Shenzhen S.E. Other stock markets 06:00:00 2024-04-24 pm EDT			5-day change	1st Jan Change
18.24 ^CNY	+0.39%		-3.34%	-37.06%

10:54am	Pharmaron Beijing Posts 34% Profit Drop in Q1 as Revenue Slips 2%	MT
10:42am	Nomura Adjusts Pharmaron Beijing Co's Price Target to HK$15.41 From HK$17.99, Keeps at Buy	MT

Pharmaron Pharmaceutical Co., Ltd. announced that it has received CNY 300 million in funding from Pharmaron Beijing Co., Ltd.

April 17, 2020

On April 18, 2020, Pharmaron (Shaoxing) Pharmaceutical Co., Ltd. closed the transaction. The company has completed the changes of business registrations of its capital increases.

Latest news about Pharmaron Beijing Co., Ltd.

Pharmaron Beijing Posts 34% Profit Drop in Q1 as Revenue Slips 2%	04:54am	MT
Nomura Adjusts Pharmaron Beijing Co's Price Target to HK$15.41 From HK$17.99, Keeps at Buy	04:42am	MT
Pharmaron Beijing To Repurchase Shares Worth Up To 300 Million Yuan; Shares Jump 8%	03:37am	MT
Pharmaron Beijing Co., Ltd. announces an Equity Buyback for CNY 300 million worth of its shares.	Apr. 25	CI
Pharmaron Beijing Co., Ltd. Announces Executive Changes	Apr. 25	CI
Pharmaron Beijing Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 25	CI
Pharmaron Beijing Co., Ltd. authorizes a Buyback Plan.	Apr. 24	CI
Pharmaron Partners Seven Firms to Float 2 Billion Yuan Fund	Apr. 08	MT
Pharmaron's 2023 Profit, Revenue Rise; Misses Estimates	Mar. 28	MT
Pharmaron Beijing Co., Ltd. Proposes Final Dividend for the Financial Year Ended December 31, 2023	Mar. 27	CI
Pharmaron Beijing Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 27	CI
Nomura Adjusts Pharmaron Beijing’s Price Target to HK$17.99 From HK$30.92, Keeps at Buy	Mar. 06	MT
Pharmaron Beijing Sees Up to 14% Jump in 2023 Profit	Jan. 29	MT
Pharmaron Forecasts Up to 19% Rise in 2023 Attributable Profit	Jan. 29	MT
Pharmaron Beijing Co., Ltd. Provides Earnings Guidance for the Financial Year Ended December 31, 2023	Jan. 28	CI
Pharmaron Beijing Buys Back Additional Series 2 Bonds	Jan. 15	MT
Pharmaron Beijing Buys Back $68 Million of Convertible Bonds Due 2026	Jan. 12	MT
Pharmaron Beijing Buys Back 705 Million Yuan of Series 2 Bonds Due 2026	Jan. 12	MT
Pharmaron's Q3 Attributable Profit Rises 6%; Shenzhen Shares Surge 12%	23-10-30	MT
Pharmaron Beijing Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-29	CI
Nomura Adjusts Pharmaron’s Price Target to 61.24 Yuan From 66.94 Yuan, Keeps at Buy	23-10-25	MT
Pharmaron's Profit Climbs 34.3% in H1	23-08-28	MT
Pharmaron Beijing Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-27	CI
Pharmaron Beijing's Profit to Jump Up to 36% in H1; Shares Jump 10%	23-07-31	MT
Pharmaron Slashes Conversion Price of Zero-Coupon Convertible Bonds Due 2026	23-07-26	MT

Chart Pharmaron Beijing Co., Ltd.

Duration

Period

More charts

Pharmaron Beijing Co. is specialised in the research, development and manufacturing of small molecule drugs, cell therapies and gene therapies. Net sales break down by activity as follows: - laboratory services (61.3%); - development and production of chemical processes and formulations (23.5%); - clinical research services (12.8%); - other (2.4%); Net sales are distributed geographically as follows: China (17.1%), Asia (2.6%), North America (64.2%), Europe (15.6%) and other (0.5%).

Sector

Biotechnology & Medical Research

Calendar

2024-08-25 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Pharmaron Beijing Co., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

18.24 CNY

Average target price

25.3 CNY

Spread / Average Target

+38.72%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
PHARMARON BEIJING CO., LTD.	-37.06%	3.94B
IQVIA HOLDINGS INC.	+1.59%	42.59B
MODERNA, INC.	+7.69%	40.65B
LONZA GROUP AG	+48.60%	40.57B
CELLTRION, INC.	-11.96%	26.77B
ICON PUBLIC LIMITED COMPANY	+8.26%	24.81B
ALNYLAM PHARMACEUTICALS, INC.	-24.27%	18.17B
MEDPACE HOLDINGS, INC.	+29.22%	12.05B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-2.93%	11.7B
UNITED THERAPEUTICS CORPORATION	+7.32%	11.1B

Other Biotechnology & Medical Research

Pharmaron Beijing Co., Ltd.

Equities

300759

CNE100003JW4

Biotechnology & Medical Research

Pharmaron Pharmaceutical Co., Ltd. announced that it has received CNY 300 million in funding from Pharmaron Beijing Co., Ltd.

Latest news about Pharmaron Beijing Co., Ltd.

Chart Pharmaron Beijing Co., Ltd.

Company Profile

Income Statement Evolution

Ratings for Pharmaron Beijing Co., Ltd.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research